文献速递免疫规划

单价奥密克戎XBB.1.5 SARS-CoV-2重组刺突蛋白疫苗在未接种且SARS-CoV-2血清阳性参与者中的免疫原性和安全性:2/3期开放标签研究第28天主要分析

Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
PubMed 文献 · Vaccine · 2025-04-02

这项2/3期开放标签单臂研究比较了未接种但既往感染SARS-CoV-2的参与者与既往接种过至少3剂mRNA疫苗的参与者,接种单剂NVX-CoV2601后第28天中和抗体应答的非劣效性。未接种组调整后GMT为1491.5,接种组为841.4,GMTR为1.8,血清应答率分别为74.3%和64.3%,未报告新的安全性信号。

要点

  • 未接种但既往感染者接种单剂NVX-CoV2601后第28天中和抗体GMT为1491.5,非劣效于既往接种者的841.4。
  • 两组血清应答率分别为74.3%和64.3%,差值10.0(95%CI 2.6-17.4)。
  • 未报告新的安全性信号或特别关注事件,疫苗耐受良好。

核心结论

  • 有SARS-CoV-2感染史的未接种参与者接种单剂NVX-CoV2601可产生稳健的中和抗体应答,非劣效于既往接种参与者。
  • 疫苗耐受良好,数据支持无论既往接种史如何均使用单剂NVX-CoV2601。

研究设计与样本

  • 2/3期开放标签单臂研究(2019nCoV-313/NCT05975060第2组),未接种且既往感染SARS-CoV-2的≥18岁参与者接种一剂NVX-CoV2601。
  • 本分析比较未接种组与既往接种组(2019nCoV-313第1组,既往≥3剂mRNA疫苗)第28天免疫原性和安全性。
  • 主要目标为未接种组相比接种组中和抗体应答的非劣效性。
  • 符合方案集包括未接种组306/338(90.5%)和接种组309/332(93.1%)。

主要发现

  • 第28天针对XBB.1.5的调整后GMT(95%CI)在未接种组为1491.5(1277.5-1741.4),接种组为841.4(723.9-978.0)。
  • 未接种组与接种组中和抗体GMTR为1.8(95%CI 1.43-2.20)。
  • 血清应答率在未接种组为74.3%,接种组为64.3%,差值10.0(95%CI 2.6-17.4)。
  • 未报告新的安全性信号或特别关注事件。

关键数值与推荐

  • 未接种组第28天调整后GMT为1491.5(95%CI 1277.5-1741.4)。
  • 接种组第28天调整后GMT为841.4(95%CI 723.9-978.0)。
  • 未接种组vs接种组中和抗体GMTR为1.8(95%CI 1.43-2.20)。
  • 未接种组血清应答率74.3% vs 接种组64.3%,差值10.0(95%CI 2.6-17.4)。

临床怎么用

  • 数据支持无论既往接种史如何均使用单剂NVX-CoV2601。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most of the population has been infected with SARS-CoV-2 and, thus, is primed by natural exposure. As such, it was assessed whether a single dose of the monovalent XBB.1.5 vaccine, NVX-CoV2601, elicited a comparable immune response to XBB.1.5 in seropositive unvaccinated participants to that in previously vaccinated participants, thereby allowing the former to forego a two-dose primary series. METHODS: In this phase 2/3, open-label, single-arm study (2019nCoV-313/NCT05975060 [group 2]), vaccine-naive participants ≥18 years with previous SARS-CoV-2 infection received one dose of NVX-CoV2601. This analysis compared the 28-day immunogenicity and safety of NVX-CoV2601 in vaccine-naive and previously vaccinated (≥3 prior mRNA-based vaccines, from 2019nCoV-313 group 1) participants. Noninferiority of neutralizing antibody (nAb) response in vaccine-naive versus vaccinated participants was the primary objective. The day-28 geometric mean titer (GMT) ratio (GMTR) and seroresponse rate (SRR; percentage of participants with a ≥4-fold rise in antibody response from baseline) were measured, and safety was assessed. RESULTS: Of the participants enrolled from September 11 to November 15, 2023, per-protocol sets included 306/338 (90.5%) vaccine-naive and 309/332 (93.1%) vaccinated participants. At day 28, adjusted GMTs (95% CI) against XBB.1.5 in the vaccine-naive and vaccinated groups were 1491.5 (1277.5-1741.4) and 841.4 (723.9-978.0), respectively. The vaccine-naive-vaccinated nAb GMTR was 1.8 (95% CI 1.43-2.20) and SRRs were 74.3% and 64.3% for vaccine-naive and vaccinated participants, respectively (SRR difference: 10.0 [95% CI 2.6-17.4]). No new safety signals or events of special interest were reported. CONCLUSIONS: A single dose of NVX-CoV2601 in vaccine-naive participants with a history of SARS-CoV-2 infection elicited a robust neutralizing antibody response that was noninferior to that observed in vaccinated participants. The vaccine was well-tolerated. These data support the use of NVX-CoV2601 as a single dose, regardless of prior vaccination history. TRIAL REGISTRATION: NCT05975060.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Alves K, Kouassi A, Plested JS, et al. Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study. Vaccine. 2025. PMID: 40184816. doi:10.1016/j.vaccine.2025.127046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。